Rossari Biotech reported Q1 FY27 record revenue of Rs. 697.2 Cr (+28% YoY) and EBITDA of Rs. 80.6 Cr (+18.7% YoY). PAT grew 4.5% to Rs. 35.1 Cr.

EBITDA margins were 11.6%, with core B2B at ~14%. Management aims for 15%+ consolidated EBITDA margins in 2-3 years by rationalizing low-margin businesses (exiting B2C), optimizing product mix, and enhancing asset utilization.

Key growth drivers include strong international business (+21% YoY), a new Thailand plant, and progress on a Saudi Arabia expansion.

New products (pharma, biosurfactants) are gaining traction.

FY27 revenue growth is guided at ~15%, with FY28 looking better from increased EO availability.

Management is confident in long-term growth and margin improvement.